GLP-1 medications work differently by targeting biological processes involved in hunger and appetite regulation
However, periodic breaks may help maintain receptor sensitivity
DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products
The glucagon receptor activity is believed to drive fat-burning and energy expenditure in ways that GLP-1-only compounds dont achieve
Example tapering schedule (for guidance only): If you are taking 4 mg once weekly: Weeks 12: reduce to 3 mg once weekly Weeks 34: reduce to 2 mg once weekly Weeks 56: reduce to 1 mg once weekly Then stop treatment
Beyond TRIUMPH: the TRANSCEND and SYNERGY programs Eli Lilly's retatrutide development extends beyond the TRIUMPH trials